Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).

被引：11
|
作者：
Byrd, John C.
Jones, Jeffrey Alan
Furman, Richard R.
Stephens, Deborah Marie
Devereux, Steve
Brown, Jennifer R.
Hillmen, Peter
Hamdy, Ahmed M.
Fardis, Maria
Tawashi, Manal
Wang, Min Hui
Patel, Priti
Mittag, Diana
Krantz, Fanny
Rothbaum, Wayne
Izumi, Raquel
O'Brien, Susan Mary
Wierda, William G.
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[2] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[4] NHS Fdn Trust Denmark Hill, Coll Hosp, London, England
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] St James Univ Hosp, Leeds, W Yorkshire, England
[7] Acerta Pharma, Santa Cruz, CA USA
[8] Pharmacycl Inc, Sunnyvale, CA USA
[9] Acerta Pharma, Redwood City, CA USA
[10] Acerta Pharma, San Carlos, CA USA
[11] Univ Calif Irvine, Irvine, CA USA
[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7521
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7521
引用
收藏
页数：2
相关论文
共 50 条
  • [1] ACALABRUTINIB, A SECOND-GENERATION BRUTON TYROSINE KINASE (BTK) INHIBITOR, IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Wierda, W.
    Jones, J.
    Furman, R.
    Stephens, D.
    Devereux, S.
    Brown, J.
    Hillmen, P.
    Hamdy, A.
    Fardis, M.
    Tawashi, M.
    Wang, M. H.
    Patel, P.
    Mittag, D.
    Krantz, F.
    Rothbaum, W.
    Izumi, R.
    O'Brien, S.
    Byrd, J.
    HAEMATOLOGICA, 2016, 101 : 151 - 151
  • [2] Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia
    Wolska-Washer, Anna
    Robak, Tadeusz
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 183 - 194
  • [3] Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
    Patel, Viralkumar
    Balakrishnan, Kumudha
    Bibikova, Elena
    Ayres, Mary
    Keating, Michael J.
    Wierda, William G.
    Gandhi, Varsha
    CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3734 - 3743
  • [4] Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia
    Ghia, Paolo
    Dlugosz-Danecka, Monika
    Scarfo, Lydia
    Jurczak, Wojciech
    LEUKEMIA & LYMPHOMA, 2021, 62 (05) : 1066 - 1076
  • [5] Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
    Woyach, Jennifer A.
    Bojnik, Engin
    Ruppert, Amy S.
    Stefanovski, Matthew R.
    Goettl, Virginia M.
    Smucker, Kelly A.
    Smith, Lisa L.
    Dubovsky, Jason A.
    Towns, William H.
    MacMurray, Jessica
    Harrington, Bonnie K.
    Davis, Melanie E.
    Gobessi, Stefania
    Laurenti, Luca
    Chang, Betty Y.
    Buggy, Joseph J.
    Efremov, Dimitar G.
    Byrd, John C.
    Johnson, Amy J.
    BLOOD, 2014, 123 (08) : 1207 - 1213
  • [6] Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?
    Stephens, Deborah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3419 - +
  • [7] Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
    Thompson, Philip A.
    Burger, Jan A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (01) : 31 - 42
  • [8] The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
    Herman, Sarah E. M.
    Montraveta, Arnau
    Niemann, Carsten U.
    Mora-Jensen, Helena
    Gulrajani, Michael
    Krantz, Fanny
    Mantel, Rose
    Smith, Lisa L.
    McClanahan, Fabienne
    Harrington, Bonnie K.
    Colomer, Dolors
    Covey, Todd
    Byrd, John C.
    Izumi, Raquel
    Kaptein, Allard
    Ulrich, Roger
    Johnson, Amy J.
    Lannutti, Brian J.
    Wiestner, Adrian
    Woyach, Jennifer A.
    CLINICAL CANCER RESEARCH, 2017, 23 (11) : 2831 - 2841
  • [9] Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
    Seymour, John F.
    Byrd, John C.
    Hillmen, Peter
    Ghia, Paolo
    Kater, Arnon P.
    Chanan-Khan, Asher
    Furman, Richard
    O'Brien, Susan M.
    Brown, Jennifer R.
    Mato, Anthony R.
    Stilgenbauer, Stephan
    Kuptsova-Clarkson, Nataliya
    Miranda, Paulo
    Wagner, Dennis
    Higgins, Kara
    Sohoni, Sophia
    Jurczak, Wojciech
    BLOOD, 2021, 138 : 3721 - +
  • [10] Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
    Stilgenbauer, Stephan
    Seymour, John F.
    Byrd, John C.
    Hillmen, Peter
    Ghia, Paolo
    Kater, Arnon P.
    Chanan-Khan, Asher
    Furman, Richard R.
    O'brien, Susan
    Brown, Jennifer R.
    Mato, Anthony
    Kuptsova-Clarkson, Nataliya
    Miranda, Paulo
    Wagner, Dennis
    Higgins, Kara
    Sohoni, Sophia
    Jurczak, Wojciech
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 169 - 169
12345